Daniel Kotok
Pulmonary Disease · Ogden, UTNPI 1427579515
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.9%), education and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Intuitive Surgical at 53.5% of the total. 2025 is the largest year on record at $2,256, more than ten times the $51 reported in 2020.
Across 70 payments — averaging $85.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Actelion Pharmaceuticals US, Inc.$757
- Sanofi$426
- GSK$386
- AstraZeneca$235
- Medtronic$173
- plus $792 from 11 others
What the payments were for
- Travel & lodging$1,30522%
- Food & beverage$3,15453%
- Education$1,50025%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $3,191 |
| Actelion Pharmaceuticals US, Inc. | 8 | $757 |
| Sanofi | 5 | $426 |
| GSK | 14 | $386 |
| AstraZeneca | 7 | $235 |
| Medtronic | 2 | $173 |
| Boehringer Ingelheim | 6 | $161 |
| Insmed, Inc. | 1 | $119 |
| Regeneron Healthcare Solutions, Inc. | 1 | $109 |
| Pulmonx Corporation | 1 | $97 |
| Merck | 1 | $86 |
| United Therapeutics Corporation | 3 | $63 |
| Boston Scientific | 3 | $58 |
| Gilead | 2 | $39 |
| Vapotherm Inc | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,898
- OPSUMIT$420
- DUPIXENT$340
- UPTRAVI$286
- ILLUMISITE$142
How this compares
$5,960 in reported general payments places this provider in the 75th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $175,141 |
| Spiriva RespimatTiotropium Bromide | 20 | $13,736 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $9,175 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,409 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $6,309 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,266 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,350 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,121 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $1,860 |
| Azelastine Hcl | 29 | $965 |
| Fluticasone Propionate | 31 | $371 |
| Prednisone | 14 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $161 | $198,05247 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $386 | $9,75922 claims |
| AstraZenecaSymbicort | $235 | $3,26613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 101 pulmonary disease providers in Utah.
Other pulmonary disease in Ogden
- Veronica WilliamsOgden$8K
- Jason KovacevicOgden$7K
- Megan PierceOgden$4K
- Anusha YelisettyOgden$3K
- Morgan CarbajalOgden$501
- Roger PaulmanOgden$194
- Mary ScholandSalt Lake City$325K
- Talaat Al ShuqairatSalem$248K
- Charles IvesterSouth Ogden$99K
- Chakravarthy ReddySalt Lake City$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.